Ryan Scott

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.

Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine in large B-cell lymphoma, results from the phase 2 LOTIS-2 trial, and future research directions with the agent.

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.

Mark D. Pegram, MD, discusses the latest data in HER2-positive metastatic breast cancer.

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.

At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with other available products.

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.

Robert J. Motzer, MD, discusses the efficacy and health-related quality of life benefits of lenvatinib/pembrolizumab in patients with advanced RCC, and projected where the regimen might fit into the treatment paradigm.